Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 September 2019 | Story Lacea Loader | Photo Stephen Collett
Dr Khotso Mokhele
Dr Khotso Mokhele, was recently honoured by the National Research Foundation.

Dr Khotso Mokhele, Chancellor of the University of the Free State (UFS), received the special 20-Year Recognition Award from the National Research Foundation (NRF) during its annual awards ceremony at the Lord Charles Hotel in Somerset West, Western Cape, on 12 September 2019. 
 
Dr Mokhele was recognised for his extraordinary, impactful, and transformative contribution to the advancement of South African science and its positioning globally.

“On behalf of the UFS Rectorate and the university community, I would like to congratulate Dr Mokhele on this fine achievement,” says Prof Francis Petersen, Rector and Vice-Chancellor of the UFS. 

“With this award, the NRF has accentuated the immense value Dr Mokhele has been bringing to not only science, but also to the many other areas he has been involved with for many years – including the UFS in his capacity as Chancellor,” says Prof Petersen. 
 
On 7 September 2019, Dr Mokhele was also named Honorary Chancellor’s Distinguished Alumnus of the Year during the UFS’s annual Chancellor’s Distinguished Alumni Awards. 

Background of Dr Mokhele

Khotso David Kenneth Mokhele was born and bred in Bloemfontein, matriculated from the Moroka High School and obtained a BSc degree in Agriculture from the University of Fort Hare, where he won the Massey-Ferguson award for the best student in his field. He continued his postgraduate studies at the University of California Davis on the prestigious Fulbright-Hays Scholarship Programme, obtaining his MSc (Food Science) and PhD (Microbiology). He was subsequently awarded postdoctoral fellowships at the Johns Hopkins University and the University of Pennsylvania in the USA. Mokhele returned to South Africa in 1987, set on becoming a top-class academic and researcher. He held lecturing posts at the Universities of Fort Hare (1987-1989) and Cape Town (1990-1992). 

In 1992, he was approached by Dr Rein Arndt, the then President of the Foundation for Research Development (FRD – the predecessor of the NRF), to join the foundation as one of its vice-presidents. The decision was a difficult one for the young Mokhele. Not only had he just embarked on an academic career, he was uncertain whether it was appropriate for a political activist to join a parastatal organisation under the apartheid government. After much soul searching, he accepted the offer on condition that he was given the freedom to transform the FRD into a funding agency geared to meeting the needs of higher education in South Africa. Shortly after he joined the FRD in June 1992, he made his presence felt as an outstanding organiser and communicator; several new research-funding programmes were initiated, with a strong emphasis on developing people who had previously been excluded. When Dr Arndt retired in 1996, Mokhele was the obvious choice to succeed him as President of the FRD. As President and CEO of the National Research Foundation (NRF) (1999-2006), Dr Mokhele played a central role in providing visionary and strategic direction to the South African science system and to the development agenda of the country. 

He was part of the team that drafted the Green Paper for science and technology, was the founder President of the Academy of Science of South Africa (ASSAF), Chairperson of the Economic Advisory Council to the Premier of the Free State (2001-2004), and a member of the Advisory Council on Innovation to the Minister of Science and Technology (2003-2007). His role in securing government and international support for the Southern African Large Telescope (SALT) Project is evidence of his dedication to science in South Africa. The success of this project laid the basis for South Africa being selected to host more than 70% of the Square Kilometre Array (SKA), an international mega-telescope for radio astronomy. He was appointed as member of the first Council on Higher Education and deputy convenor of its task force on the Reconfiguration of Higher Education, and he served on the councils of a number of universities. More recently, he was appointed by the Minister of Science and Technology as a member of the National Advisory Council on Innovation, and by the Minister of Labour as chair of the National Skills Board. 

His role in science is recognised internationally. In achieving his vision, he recognised the importance of South Africa’s re-entry into the international science community and has been an ambassador for South African and African science in high-profile international fora. He was elected Vice-President: Scientific Planning and Review of the International Council for Sciencee (ICSU) and as Chairperson of its Committee for Scientific Planning and Review (2005-2008), as well as a member of the Committee on Developing and Transition Economy Countries of the International Social Science Council (2008-2010). He also represented South Africa on the executive board of UNESCO (1997-2001) and served as Chairperson of the Special Committee of this board (1999-2001). Dr Mokhele was part of the UNESCO assignment (2006-2007) to review the science and technology system of the member states of the Caribbean Community (CARICOM) and giving advice on how to leverage science, technology, and innovation for the development of the Caribbean region. 

Dr Mokhele’s corporate positions included Non-Executive Chairman on the Board of Directors of Impala Platinum Holdings Ltd (Implats), ArcelorMittal South Africa, and Adcock Ingram Holdings Ltd; Non-Executive Director of African Oxygen Ltd (Afrox), Zimbabwe Platinum Holdings Ltd (Zimplats), Mapitso Consortium, Kenosi Investment Holdings, and Tiger Brands Ltd. He is the President of the Hans Merensky Foundation (South Africa) and a trustee of SciDev.Net (a web-based scientific magazine based in London, UK) and Start International Inc (a global-change capacity-building initiative based in the USA). He was Chairman of the Rhodes Scholarship Selection Committee for Botswana, Malawi, Namibia, Lesotho, and Swaziland (2007–2011) and has served on the South Africa at Large Rhodes Scholarship Selection Committee for more than 10 years. 

Khotso Mokhele’s contribution to science in South Africa has received wide recognition locally and abroad. He has received six honorary doctorates, the most recent from Rutgers University in the USA. He was made a Chevalier of the Legion of Honour by the President of France in recognition of his personal efforts in strengthening scientific ties between France and South Africa, and was appointed a director of the Salzburg Global Seminar – an institution focused on global change, and subsequently as member of its Council of Senior Fellows. He was the recipient of the Technology Top 100 Lifetime Achievers Award in 2009, and the National Science and Technology Forum Award in 2005. He also received the Science Diplomacy Award from the Minister of Science and Technology in South Africa (2015). 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept